Skip to main content
. 2019 Apr 30;27(5):1461–1471.e4. doi: 10.1016/j.celrep.2019.04.014

Figure 6.

Figure 6

AIP Is Overexpressed in Human DLBCLs

(A) AIP is expressed in many tumors, and AIP was found to be most highly expressed in DLBCLs. Data were obtained from http://www.ciobioportal.org.

(B) AIP staining from reactive lymph nodes (n = 88 mean 13 ± 2.5) and DLBCL biopsies (n = 74 mean 20 ± 2.5) ∗∗∗p < 0.0001 (two-tailed Mann-Whitney U test).

(C) Survival analysis of DLBCL patients with high and low AIP expression. Data obtained from http://www.genomicscape.com/.

(D) BCL6 and AIP protein expression in DLBCL cell lines.

(E) Ratio between AIP and BCL6 expression. EBV, Epstein-Barr-virus-infected B cells; PB, peripheral blood B cells.

(F) Lentiviral delivery of scrambled or shRNAi against Aip to OC1-LY7 cells. Cells were examined 48 h after transfection, and the expression of AIP and BCL6 and cell viability were analyzed by flow cytometry.

(G) Diagram showing the interaction between FBXO11, UCHL1, BCL6, and AIP. Under genotoxic environments found in GC B cells or DLBCL cells, AIP brings UCHL1 to deubiquitinate BCL6, thus maintaining its expression. In the absence of AIP, BCL6 gets ubiquitinated by FBXO11 and undergoes proteasomal degradation. ∗∗∗p < 0.0001 (a Mann-Whitney U test).